UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000027210 |
|---|---|
| Receipt number | R000031178 |
| Scientific Title | A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G) |
| Date of disclosure of the study information | 2017/05/01 |
| Last modified on | 2022/03/01 13:36:34 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)
Acronym
A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients(WJOG8916G)
Scientific Title
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)
Scientific Title:Acronym
A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients(WJOG8916G)
Region
| Japan |
Condition
Condition
Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-epidermal growth factor receptor(EGFR) antibodies
Classification by specialty
| Gastroenterology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to investigate the efficacy and tolerability of TAS-102 in combination with cetuximab for patients with metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-EGFR antibodies.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
disease control rate
Key secondary outcomes
overall survival , progression free survival , response rate , safety
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
TAS-102
35 mg/m2, orally BID
The evening of Day 1 to the morning of Day 6,Evening of Day 8 to the morning of Day 13, every 28 days
Cetuximab
Initial dose is 400 mg/m2, the subsequent weekly doses are 250 mg/m2
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)histopathologically confirmed unresectable or metastatic colorectal adenocarcinoma
2) Wild-type RAS status
3) Measurable disease by response evaluation criteria in solid tumors (RECIST version 1.1) criteria
4) refractory disease or unable to tolerate agents (fluoropyrimidines, irinotecan, oxaliplatin) and antiangiogenic agent (bevacizumab,ramucirumab and aflibercept) , and refractory to anti-EGFR antibodies (cetuximab and panitumumab)
5) No prior TAS-102
6) Patients who have not had major surgery (i.e., thoracotomy or laparotomy) within 4 weeks prior to enrollment.
7) Patients who have not had radiotherapy for bone and/or brain metastases excluding primary colorectal cancer within 2 weeks prior to enrollment
8) Patients who have not had any chemotherapy within 2 weeks prior to enrollment
9) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
10) An estimated life expectancy of at least 12 weeks after enrollment
11) Is able to take medications orally
12) Patients must have the following adequate organ functions
13) Ability to understand and the willingness to sign a written informed consent document
Key exclusion criteria
1) Previous grade 3/4 hypersensitivity reaction to Cmab
2) Another malignancy with less than 5 disease-free years
3) Presence of active local or systemic infection under treatment
4) Positive for Hepatitis B surface antigen
5) Radiographic evidence of severe pulmonary fibrosis or interstitial pneumonia on Computed Tomography
6) Symptomatic brain and/or leptomeningeal metastases which needs treatment
7) Serious complications
8) Clinically significant mental or psychological disorder
9) Patients requiring continuous treatment with systemic steroids
10) Females who are pregnant, breastfeeding, or with a positive pregnancy test or males and females of reproductive potential unwilling to use adequate contraception
11) Patients whose participation in the trial was judged to be inappropriate by the attending doctor
Target sample size
55
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Naoki Izawa |
Organization
St. Marianna University School of Medicine
Division name
Department of Clinical Oncology
Zip code
Address
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511
TEL
044-977-8111
n2izawa@gmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shinichiro Nakamura |
Organization
West Japan Oncology Group
Division name
WJOG datacenter
Zip code
Address
Namba Plaza Bldg.304-1-5-7,Motomachi Naniwa-ku,Osaka556-0016 JAPAN
TEL
06-6633-7400
Homepage URL
datacenter@wjog.jp
Sponsor or person
Institute
West Japan Oncology Group
Institute
Department
Personal name
Funding Source
Organization
Merck Serono Co., Ltd.,Taiho Pharmaceutical Co.,Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 05 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 04 | Month | 28 | Day |
Date of IRB
| 2017 | Year | 06 | Month | 30 | Day |
Anticipated trial start date
| 2017 | Year | 07 | Month | 04 | Day |
Last follow-up date
| 2021 | Year | 06 | Month | 13 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 05 | Month | 01 | Day |
Last modified on
| 2022 | Year | 03 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031178
